BioStock: No protection — no value! Why IP matters to the life science investor | Health & Wealth #4

Intellectual Property or ”IP” might sound like a boring topic to some, but if you are an inventor or an investor, you should pay close attention. Why? Because poor IP protection of an ever so promising new drug, or a groundbreaking medical device could effectively render the asset more or less worthless. We invited Benjamin Hoffmann, patent lawyer and legal expert with Europe’s leading IP law firm Potter Clarkson, to explain the fundamental importance of IP from an investor’s perspective.

Listen and learn about which red flags to look for when investing, why Big Pharma calculate down to the exact day when a patent runs out and how you can tell if the company you are about to invest in has a strong or weak patent protection.

Se intervjun på biostock.se:

https://www.biostock.se/health-and-wealth/?utm_source=mail&utm_medium=mail&utm_campaign=hw&utm_id=hw

Detta är ett pressmeddelande från BioStock – Connecting Innovation & Capital. https://www.biostock.se